<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052607</url>
  </required_header>
  <id_info>
    <org_study_id>IbnSina-PPOS</org_study_id>
    <nct_id>NCT04052607</nct_id>
  </id_info>
  <brief_title>Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol for Freeze-all Cycles</brief_title>
  <acronym>ANTA-PPOS</acronym>
  <official_title>Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol on Live Birth Rate for Freeze-all Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ibn Sina Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ibn Sina Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stimulation protocols for IVF underwent several cycles of upgrading aiming to achieve
      reasonable outcomes with low-cost cycles. Antagonist protocols have been introduced as
      effective and comparable to long agonist regarding the outcomes. However, these protocols are
      still costly. Alternative protocols using progestin suppressions appear options for
      consideration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth after first Vitrified-warmed cycle</measure>
    <time_frame>42 weeks of gestation</time_frame>
    <description>Delivery of one or more viable infants &gt; 20th weeks of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>14 days after egg retrieval</time_frame>
    <description>positive human chorionic Gonadotrophin (βhCG) ≥ 10 IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>within 12 weeks of gestation</time_frame>
    <description>registered sacs with a heartbeat on ultrasound at 7th weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>within 24 weeks of pregnancy</time_frame>
    <description>continued viable pregnancy &gt; 20th weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage</measure>
    <time_frame>Within 20 weeks of pregnancy</time_frame>
    <description>loss of pregnancy ≤ 20th weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Term live-birth for vitrified-warmed transfer</measure>
    <time_frame>Within 42 weeks of gestation</time_frame>
    <description>Delivery of one or more viable infants ≥37 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth</measure>
    <time_frame>Within 42 weeks of gestation</time_frame>
    <description>delivery of one or more viable infants &lt; 37th weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very preterm birth</measure>
    <time_frame>Within 42 weeks of gestation</time_frame>
    <description>delivery of one or more viable infants &lt; 32nd weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight babies</measure>
    <time_frame>Within 24 hours of delivery</time_frame>
    <description>Babies with &lt; 2500 gm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital malformation</measure>
    <time_frame>Within one month of delivery</time_frame>
    <description>delivery of congenitally malformed babies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Still birth</measure>
    <time_frame>Within 42 weeks of gestation</time_frame>
    <description>delivery of nonviable babies &gt; 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative live birth</measure>
    <time_frame>One year from randomization</time_frame>
    <description>Registered viable neonates after two vitrified-warmed transfers within one year of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>presence of 2 pronuclei 17±1 hr after oocyte injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo cleavage</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>Cleaved embryos per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top-quality embryo on day 3</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>(7-8 cells with appropriate-sizes blastomeres and less than 10% fragmentation by volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blastocyst formation on day 5 or 6</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>formed blastocysts per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top-quality blastocyst on day 5</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>Rounded and dense inner cell mass with many trophectodermal cells creating a connected zone and a blastocoel more than 100% by volume; ≥ 311 grade per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryopreservation</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>Cryopreserved embryos per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live-birth-implantation rate</measure>
    <time_frame>Within 42 weeks of gestation</time_frame>
    <description>Number of viable neonates per number of embryos transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilized embryos</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>Number of cryopreserved plus transferred embryos per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top-quality utilized embryos</measure>
    <time_frame>Within 6 days of culture</time_frame>
    <description>Number of high-quality embryos transferred plus cryopreserved per fertilized oocyte</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metaphase II oocyte</measure>
    <time_frame>Within 24 hours of oocyte retrieval</time_frame>
    <description>Mature oocyte per oocyte collected</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone Suppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent luteinizing hormone (LH) surge. The stimulation is with 150-300 IU FSH/HMG starting on cycle day 2 and adjusted according to the AFC and AMH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dydrogesterone Suppression with minimal stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dydrogesterone 30 mg on stimulation day 5 till the trigger day to prevent LH surge. The stimulation is with clomifene citrate 50 mg three times daily with150 IU FSH starting on cycle day 2 and continued every other day and adjusted according to the AFC and AMH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antagonist Suppression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cetrorelix acetate 0.25 started on stimulation day 6 till the trigger day to prevent LH surge. The stimulation is with150-300 IU FSH starting on cycle day 2 and continued daily and adjusted according to the AFC and AMH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LH Suppression</intervention_name>
    <description>Stimulation protocols</description>
    <arm_group_label>Antagonist Suppression</arm_group_label>
    <arm_group_label>Dydrogesterone Suppression</arm_group_label>
    <arm_group_label>Dydrogesterone Suppression with minimal stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women age of ≥ 18 to ≤ 40;

          2. BMI of ≤ 31;

          3. All indication for freeze-all

          4. PCOS;

          5. Women who have ≥ 1 year of primary or secondary infertility;

          6. Tubal factor (unilateral, bilateral obstruction or salpingectomy);

          7. Fresh ejaculate sperm of any count provided they have ≥ 1% normal forms and a motile
             fraction;

          8. Women undergoing their first ICSI cycle or following a previous successful attempt;

          9. Women undergoing only frozen-thawed embryo transfer;

         10. Women with &gt; 8 mm endometrial thickness at the day of progesterone supplementation in
             the transfer cycle;

         11. Women with no detected uterine abnormality on transvaginal ultrasound (e.g. submucosal
             myomas, polyps or septa).

        Exclusion Criteria:

          1. Unilateral oophorectomy;

          2. Uterine pathology or abnormality;

          3. Abnormal karyotyping for them or their male partners;

          4. History of repeated abortions or implantation failure;

          5. Uncontrolled diabetes;

          6. Liver or renal disease;

          7. History of malignancy or borderline pathology;

          8. Endometriosis;

          9. Plan for PGD-A;

         10. Severe male factor includes surgical sperm retrieval or cryopreserved sperm.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Fawzy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ibnsina Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Fawzy</last_name>
    <phone>+201011122286</phone>
    <email>drfawzy001@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banon Fertility Center</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Mahran, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ahmed Nabil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mai Emad, Embryologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IbnSina IVF Center, IbnSina Hospital</name>
      <address>
        <city>Sohag</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Fawzy, Lab Director</last_name>
      <phone>+201011122286</phone>
      <email>drfawzy001@me.com</email>
    </contact>
    <investigator>
      <last_name>Mohamed Fawzy, Lab Director</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AlRahma Hospital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Y AbdelRahman, MD</last_name>
      <phone>+201124309985</phone>
      <email>dryahyaz@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ibn Sina Hospital</investigator_affiliation>
    <investigator_full_name>Muhammad Fawzy</investigator_full_name>
    <investigator_title>IVF Lab Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

